Clinical efficacy of the combined use of two medicinal forms of recombinant interferon α -2b in the treatment of infectious mononucleosis in children

Justify the need to include two medicinal forms of recombinant interferon α -2b in combination with highly active antioxidants vitamins E and C (VIFERON®) in the form of rectal suppositories and gel for external use in the treatment of infectious mononucleosis in children.

A clinical and laboratory examination of 115 children with infectious mononucleosis aged 3 to 11 years was carried out. Depending on the treatment, the patients were divided into three groups: the first group consisted of 50 children who received combination therapy with recombinant interferon α -2b (rIFN- α -2b, VIFERON®) in the acute period of the disease in the form of rectal suppositories and a gel for external use . The second group of children (35 people) received only rIFN- α -2b in the acute period of the disease in the form of rectal suppositories. The comparison group (III) was 30 people who received only pathogenetic and symptomatic therapy in the acute period of the disease.

Combined therapy with recombinant interferon α -2b in combination with highly active antioxidants, vitamins E and C (VIFERON®), as rectal suppositories and gel for external use, significantly improved the clinical and laboratory manifestations of the disease and shortened the duration of stay in a hospital not only with group of comparison, but also with patients of group II who received recombinant interferon α -2b (VIFERON®) only in the form of rectal suppositories.

The conclusion. The combined use of recombinant interferon α -2b (VIFERON®) in the form of rectal suppositories and gel for external use may be recommended for the treatment of infectious mononucleosis in children.

1. Eokovoj A.G. Herpesvirus infections in children and parents: A manual for students, pediatricians, infectionists, immunologists. M.: Cen-tr strategicheskoj konyunktury, 2014: 256. (In Russ.)

2. Goncharova E.V, Senyuta N.B., Smirnova K.V., Sherbak L.N., Gurcevich V.Eh. Epstein-Barr virus (VEB) in Russia: infection of the population and analysis of variants of the LMP1 gene in patients with VEB-associated pathologies and in healthy individuals. Voprosy Virusologii. 2015. 60(2):1 1—17. (In Russ.)

3. Kharlamova F.S., N.Yu. Yegorova, O.V. Shamsheva, V.F. Uchaikin, O.V. Molochkova, E.V. Novosad, T.M. Lebedeva, E.V. Simonov.The role of herpes virus IV, V and VI types in infectious and somatic pathology in children. Pediatriya=Pediatrics. 2017. 96(4):42—47. (In Russ.) DOI: 10.24110/0031-403X-2017-96-4-42-47

4. Andreeva A.A., Ikkes L.A. Clinico-hematological characteristics of infectious mononucleosis caused by the Epstein-Barr virus, in children of the first year of life. Sibirskoe Medicinskoe Obozrenie. 2016. 100(1):91—99. (In Russ.)

5. Egorova N.Y., Molochkova O.V., Guseva L.N., Waltz N.L., Chusov K.P. Active Herpes Virus Infection in Young Children. Detskie Infekt-sii=Children's Infections. 2018;17(4):22-28. (In Russ.) https://doi.org/10.22627/2072-8107-2018-17-4-22-28

6. Timchenko VN. Diseases of civilization (measles, VEB mononucleosis) in pediatric practice: A guide for doctors. Sankt-Peterburg: Spe-cLit, 2017:527. (In Russ.)

7. Bokovoj A.G. Herpetic infections as a leading factor in the formation of secondary immunodeficiency in childhood. Ehpidemiologiya i Infekcionnye Bolezni. 2007. 6:34—38. (In Russ.)

8. Levina A.S., G.F. ZHeleznikova, V.V. Ivanova et al. The effectiveness of immunocorrective therapy in infectious mononucleosis in children Detskie Infektsii=Children's Infections. 2009. 1:60—63. (In Russ.)

9. Kurtasova L.M., Shakina N.A., Ikkes L.A. Change in the sensitivity of peripheral blood leukocytes to interferon- α 2 in vitro in children with infectious mononucleosis caused by the Epstein-Barr virus in the course of the disease. Infekciya i Immunitet. 2017. 7(1):85—90. (In Russ.)

10. Keshishyan E.S., Zenina O.M., Kushnareva M.V Effectiveness of local immunoprophylaxis ORI in young children in general osmotic departments. Effective pharmacokinetics. Pediatriya=Pediatrics. 2014. 5:50—54. (In Russ.)

11. 1. Ershov F.I., Narovlyanskij A.N. Use of interferon inducers for viral infections. Voprosy Virusologii. 2015. 60(2):5—10. (In Russ.)

12. Оспельникова Т.П. Роль интерферона при гриппе и генитальном герпесе. Вопросы вирусологии. 2013. 5: 4—10. Ospel'nikova T.P. The role of interferon in influenza and genital herpes. Voprosy Virusologii. 2013. 5: 4—1 0. (In Russ.)

13. Kikuchi K., Inoue H., Miyazaki Y., Ide F., Kojima M., Kusama K. Epstein-Barr virus (EBV)-associated epithelial and non-epithelial lesions of the oral cavity. The Japanese dental science review. 2017. 53(3):95—1 09.

14. Goswami R., K. H. Shair, E. Gershburg. Molecular diversity of IgG responses to Epstein-Barr virus proteins in asymptomatic Epstein-Barr virus carriers. The Journal of General Virology. 2017. 998(9):2343—2350.